Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:1634-1638

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stec, J. J.
Right arrow Articles by D’Agostino, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stec, J. J.
Right arrow Articles by D’Agostino, R. B., Sr
Related Collections
Right arrow Risk Factors
Right arrow Peripheral vascular disease
Right arrow Acute myocardial infarction
Right arrow Risk Factors for Stroke
Right arrow Chronic ischemic heart disease
Right arrow Epidemiology
Right arrow Coagulation and fibronolysis

(Circulation. 2000;102:1634.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population

James J. Stec, BS; Halit Silbershatz, PhD; Geoffrey H. Tofler, MD; Travis H. Matheney, MLA; Patrice Sutherland, BS; Izabela Lipinska, PhD; Joseph M. Massaro, PhD,; Peter F.W. Wilson, MD; James E. Muller, MD; Ralph B. D’Agostino, Sr, PhD

From the Institute for Prevention of Cardiovascular Disease, Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School (J.J.S., G.H.T., I.L., JE.M.); Boston University, Mathematics and Statistics Department (H.S., R.B.D’A.); and Boston University School of Public Health, Department of Epidemiology and Biostatistics (J.M.M.), Boston, Mass; and the National Heart, Lung and Blood Institutes, Framingham Heart Study and National Institutes of Health (T.H.M., P.S., P.F.W.W.), Framingham, Mass.

Correspondence to Ralph B. D’Agostino, PhD, Boston University, Mathematics and Statistics Department, 111 Cummington St, Boston, MA 02215. E-mail ralph{at}bu.edu

Background—Fibrinogen has been identified as an independent risk factor for cardiovascular disease and associated with traditional cardiovascular risk factors. Also, the role of elevated fibrinogen in thrombosis suggests that it may be on the causal pathway for certain risk factors to exert their effect. These associations remain incompletely characterized. Moreover, the optimal fibrinogen assay for risk stratification is uncertain.

Methods and Results—In 2632 subjects from cycle 5 of the Framingham Offspring Population, fibrinogen levels were determined with a newly developed immunoprecipitation test (American Biogenetic Sciences) and the functional Clauss method. With the immunoprecipitation method, there were significant linear trends across fibrinogen tertiles (P<0.001) for age, body mass index, smoking, diabetes mellitus, total cholesterol, HDL cholesterol, and triglycerides in men and women. The Clauss method had significant results (P<0.030), except for triglycerides in men. Fibrinogen levels were higher for those with compared with those without cardiovascular disease. After covariate adjustment, fibrinogen remained significantly higher in those with cardiovascular disease with the use of the immunoprecipitation test (P=0.035 and P=0.018 for men and women, respectively) but not with the Clauss method.

Conclusions—Fibrinogen was associated with traditional cardiovascular risk factors. Elevation of fibrinogen may provide a mechanism for risk factors to exert their effect. Also, fibrinogen levels were higher among subjects with cardiovascular disease compared with those without disease. The immunoprecipitation test showed a stronger association with cardiovascular disease than the Clauss method, suggesting that it may be a useful screening tool to identify individuals at increased thrombotic risk.


Key Words: fibrinogen • cardiovascular disease • Framingham Offspring Study




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
I. Mertens, R. V Considine, M. Van der Planken, and L. F Van Gaal
Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin?
Eur. J. Endocrinol., September 1, 2006; 155(3): 477 - 484.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Feinbloom and K. A. Bauer
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. M. Soria, L. Almasy, J. C. Souto, A. Buil, M. Lathrop, J. Blangero, and J. Fontcuberta
A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels
Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1287 - 1292.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
E. B. Loucks, L. F. Berkman, T. L. Gruenewald, and T. E. Seeman
Social Integration Is Associated With Fibrinogen Concentration in Elderly Men
Psychosom Med, May 1, 2005; 67(3): 353 - 358.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
E. Arikan and S. Sen
Endothelial Damage and Hemostatic Markers in Patients with Uncomplicated Mild-to-Moderate Hypertension and Relationship with Risk Factors
Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 147 - 159.
[Abstract] [PDF]


Home page
Mayo Clin Proc.Home page
I. J. Kullo and C. M. Ballantyne
Conditional Risk Factors for Atherosclerosis
Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E.-G. V. Giardina, H. J. Chen, R. R. Sciacca, and L. E. Rabbani
Dynamic Variability of Hemostatic and Fibrinolytic Factors in Young Women
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6179 - 6184.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
W. H Reinhart
Fibrinogen - marker or mediator of vascular disease?
Vascular Medicine, August 1, 2003; 8(3): 211 - 216.
[Abstract] [PDF]


Home page
Diabetes CareHome page
R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group
Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort
Diabetes Care, May 1, 2003; 26(5): 1439 - 1448.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Vlassara, W. Cai, J. Crandall, T. Goldberg, R. Oberstein, V. Dardaine, M. Peppa, and E. J. Rayfield
Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy
PNAS, November 26, 2002; 99(24): 15596 - 15601.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. ZANOBETTI and J. SCHWARTZ
Are Diabetics More Susceptible to the Health Effects of Airborne Particles?
Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 831 - 833.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K.G. Jones, D.J. Brull, L.C. Brown, M. Sian, R.M. Greenhalgh, S.E. Humphries, and J.T. Powell
Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms
Circulation, May 8, 2001; 103(18): 2260 - 2265.
[Abstract] [Full Text] [PDF]